Veopoz® (pozelimab-bbfg)

Veopoz (pozelimab‑bbfg) is covered for CD55‑deficient protein‑losing enteropathy (CHAPLE) in patients ≥1 year with genetic confirmation of biallelic CD55 loss‑of‑function variants, serum albumin ≤3.2 g/dL, active disease within the past 6 months, and when prescribed by a physician experienced in CHAPLE; use is not covered if age <1, genetic confirmation, albumin threshold, recent active disease, or prescriber expertise are lacking. Initial approval (3 months) requires genetic, albumin, and clinical documentation; reauthorization (12 months) requires documented clinical response, and dosing is 30 mg/kg IV loading on Day 1 then 10 mg/kg SC weekly from Day 8 (may escalate to 12 mg/kg weekly up to 800 mg max after ≥3 weekly doses if inadequate response).

"Veopoz is indicated for the treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE (complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy) disease."